Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA8 | P11142 | 3/20 | 1.00 |
| ▸ | HSPA5 | P11021 | 2/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.73 |
| ▸ | GAPDH | P04406 | 3/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | HBB | P68871 | 1/20 | 0.69 |
| ▸ | FBP1 | P09467 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.66 |
| ▸ | SLC28A2 | O43868 | 2/20 | 0.65 |
| ▸ | DPP4 | P27487 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.65 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1145049 | 1.00 | HSPA8 (1.00) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL17412455 | 1.00 | HSPA8 (1.00) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| Phosphoric Acid SCHEMBL10528492 | 0.94 | HSPA8 (0.89) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| Phosphoric Acid SCHEMBL636534 | 0.94 | HSPA8 (0.89) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL17406911 | 0.89 | HSPA8 (0.80) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL6305168 | 0.89 | HSPA8 (0.80) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL14779383 | 0.89 | HSPA8 (0.80) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL6434241 | 0.89 | HSPA8 (0.80) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL18858928 | 0.89 | HSPA8 (0.80) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL1135195 | 0.89 | HSPA8 (0.80) | HSPA8HSPA5RXFP1GAPDHHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129045-A1 | SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-04-24 | — | — | US | claimed |
| WO-2024167952-A1 | OXIDATIVELY CLEAVABLE ORGANOPHOSPHATE DRUGS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-08-15 | — | — | WO | claimed |
| WO-2023150534-A1 | SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-08-10 | — | — | WO | claimed |
| WO-2022173711-A9 | METHOD OF TREATING CANCER WITH NUCLEOTIDE THERAPEUTICS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-10-06 | — | — | WO | claimed |
| WO-2022173711-A1 | METHOD OF TREATING CANCER WITH NUCLEOTIDE THERAPEUTICS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-08-18 | — | — | WO | claimed |
| US-20220249534-A1 | METHOD OF TREATING CANCER WITH NUCLEOTIDE THERAPEUTICS | THE GENERAL HOSPITAL CORPORATION | 2022-08-11 | — | — | US | claimed |
| EP-2360166-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | Merck Sharp & Dohme Corp. (US) | 2011-08-24 | — | — | EP | claimed |
| EP-1814390-A4 | METHODS OF TREATING HEMATOLOGICAL MALIGNANCIES WITH NUCLEOSIDE ANALOG DRUGS | UNIV NORTHWESTERN (US) | 2009-07-01 | — | — | EP | claimed |
| US-20090082304-A1 | Methods of Treating Hematological Malignancies with Nucleoside Analog Drugs | NORTHWESTERN UNIVERSITY (US) | 2009-03-26 | — | — | US | claimed |
| EP-1814390-A2 | METHODS OF TREATING HEMATOLOGICAL MALIGNANCIES WITH NUCLEOSIDE ANALOG DRUGS | Northwestern University (US) | 2007-08-08 | — | — | EP | claimed |
| WO-2006053252-A2 | METHODS OF TREATING HEMATOLOGICAL MALIGNANCIES WITH NUCLEOSIDE ANALOG DRUGS | NORTHWESTERN UNIVERSITY (US) | 2006-05-18 | — | — | WO | claimed |
| EP-1539188-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | claimed |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | MERCK SHARP & DOHME LLC | 2004-06-10 | — | — | US | claimed |
| WO-2002057425-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK & CO., INC. (US) | 2002-07-25 | — | — | WO | claimed |
| EP-4746905-A1 | RSV VACCINE | Astrazeneca AB (SE) | 2026-05-27 | — | — | EP | disclosed |
| US-20250368996-A1 | MODIFIED ANTISENSE OLIGONUCLEOTIDES FOR TREATING HEPATITIS B VIRUS | ALIGOS THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250129045-A1 | SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-04-24 | — | — | US | disclosed |
| US-4791055-A | ENZYME-CLEAVABLE BONDS | MILES INC. (US) | 1988-12-13 | — | — | US | disclosed |
| US-4629688-A | CLINICAL ANALYSIS | MILES LABORATORIES, INC. (US) | 1986-12-16 | — | — | US | disclosed |
| US-4383031-A | LIGANDS; IMMUNOASSAY; SIMPLIFICATION; DIAGNOSIS/MEDICAL/ | MILES LABORATORIES, INC. (US) | 1983-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | NSUN2, NSUN3, POLRMT | HSPA8 3709/4885HSPA5 1811/4885RXFP1 4698/4885 |
| US-20250368996-A1 | MODIFIED ANTISENSE OLIGONUCLEOTIDES FOR TREATING HEPATITIS B VIRUS | HAVCR2, SNRPB2, NSUN2 | HSPA8 1293/4885HSPA5 1281/4885RXFP1 4253/4885 |
| US-20250129045-A1 | SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF | PIM3, PIM1, PIM2 | HSPA8 1376/4885HSPA5 2551/4885RXFP1 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.